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SUMMARY – Based on immunohistochemical staining for the basal markers cytokeratin 5/6 
(CK 5/6), cytokeratin 14 (CK 14) and P-cadherin, triple negative tumors (TNT) are divided into 
two groups: 1) basal-like (BL) positive for one or all three markers; and 2) non basal-like (NBL) 
negative for all three markers. Even though the different origin of the cells of these two types of 
tumors implies different biological properties, they had been treated as one entity until recently. This 
paper analyzes TNT collected from 150 patients and distributed into two groups according to the 
results of immunohistochemical analysis, i.e. BL 116 (77.3%) and NBL 34 (22.67%). In this study, 
CK 5/6, CK 14 and P-cadherin were used as markers for identifying BL tumors. The immunohi-
stochemical reaction was positive for CK 5/6 in 37%, for CK 14 in 50.86% and for P-cadherin in 
68.34% of cases. The subclassification of triple negative breast cancer using the basal markers CK 
5/6, CK 14 and P-cadherin has enabled identification of BL and NBL breast cancers in a proportion 
that is in line with the only accurate analysis of TNT gene expression. Using the mentioned combi-
nation of markers in daily practice is easy to perform and economically affordable.
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Introduction
The tumors whose cells do not express three groups 
of receptors, i.e. estrogen (ER), progesterone (PR) and 
human epidermal growth factor (HER2) receptors, 
pose a particular problem and huge enigma in breast 
cancer treatment. The tumors with these characteris-
tics are called triple negative tumors (TNT) and they 
account for 15%-20% of all breast tumors. This diag-
nostic profile is in line with the aggressive behavior 
of the neoplasm, its increased risk of metastasis, and 
most importantly, very poor response to treatment1-4.
The triple negative group of breast tumors is not 
homogeneous. According to the latest findings of 
gene expression analysis and immunohistochemical 
differentiation methods, the triple negative tumors 
can be distributed into two subgroups, depending on 
the source of cancer cells. One subgroup consists of 
TNT originating from basal canal cells, the so called 
basal-like carcinoma. They account for 71%-91% of 
the triple negative breast cancers (TNBC). The sec-
ond subgroup consists of about 9%-29% of TNT that 
do not originate from basal cells and are thus called 
non basal-like. Even though the different origin of the 
cells of these two types of tumors implies different 
biological properties, they had been treated as one en-
tity until recently5-7.
4 Acta Clin Croat,  Vol. 55,   No. 1,  2016
M. Lesar et al. Immunohistochemical differentiation of triple negative breast cancer
In clinical practice, the grouping of TNT can be 
done through immunohistochemical marking of the 
basal-like tumors using the so called basal markers. It 
is assumed that these tumors originate from the outer 
basal layer of the cells that show signs of both epithelia 
and smooth muscles and are therefore called myoepi-
thelial (ME) cells. ME cells are defined as basal cells 
as they are located next to the basal membrane of the 
ductus and the acinus. They show high expression of 
basal cytokeratins (CK 5/6, CK 14, CK 8/18, CK 17), 
P-cadherin, p63, vimentin, epidermal growth factor 
receptors (EGFR1) and c-kit8,9.
In order to increase the precision of immunohis-
tochemical distribution of tumors into basal-like and 
non basal-like, it is necessary to use as many differ-
ent markers as possible, such as CK 5/6, CK 14, CK 
17, EGFR, P-cadherin, vimentin, fascin, nestin and 
moesin; they can be used individually or in combina-
tion. By using each of the 9 markers for TNT, the 
ratio of basal-like tumors would be up to 94% and this 
would include those tumors that are not in correlation 
with the results gained through a valid gene expres-
sion analysis.
Generally speaking, an increase in the number 
of markers increases test specificity and sensitivity10. 
However, as there is no such consensus on the cri-
terion for identifying basal like tumors through im-
munohistochemical analysis, it is recommendable to 
use a limited number of markers, such as: CK 5/6, CK 
14, CK 17, P-cadherin and EGFR5,11. In order to de-
termine the best combination, the one that would be 
closest to the results of the gene expression analysis, in 
this study CK 5/6, CK 14 and P-cadherin were used 
as markers for identifying basal-like tumors. 
Materials and Methods
The research was conducted on 150 samples of 
triple negative (TNT, no expression of estrogen, pro-
gesterone and HER2 receptors) invasive ductal breast 
carcinoma obtained during surgical procedures from 
patients in various stages of the disease. Patient age at 
the time of the procedure ranged from 32 to 82. Each 
patient had a breast segment removed along with the 
accompanying tumor (segmentectomy) and the re-
lated axillary lymph node, or the entire breast with 
the tumor (ablation) along with the related axillary 
lymph node. 
Two cuts of the paraffin block of each tumor tis-
sue sample were used in receptor (estrogen and pro-
gesterone) demonstration. Two mouse monoclonal 
antibodies were used (estrogen, DAKO, Denmark, 
N0 H 7098, ready to use; and progesterone, DAKO, 
Denmark, N0 M 3569, 1:50). Immunohistochemi-
cal staining was performed via automated use of the 
DAKO autostainer universal staining system machine 
and the Microwave Streptavidin ImmunoPeroxidase 
(MSIP) method, with the use of kit (DAKO; K 5007, 
according to the manufacturer’s instructions), which 
contained the secondary HRP antibody, rabbit/mouse 
DAKO RealTM En VisionTM. The results of the immu-
nohistochemical analysis were shown semi-quantita-
tively by determining the percentage of positive cells 
(for a certain protein).
On semi-quantitative determination of the HER2 
protein value, the HercepTest (K5204 package, 
DAKO, Denmark) containing all necessary reagents 
for proving the reaction was used. Primary mouse 
antibodies for human HER2 protein, secondary goat 
antibodies against rabbit immunoglobulin and visu-
alization reagents – horseradish peroxidase bound to 
dextran polymer were used. The test has been approved 
by the United States Food and Drug Administration. 
By determining the expression of CK 5/6, CK 14 and 
P-cadherin, the triple-negative invasive ductal breast 
carcinoma can be divided into so called basal-like and 
non basal-like carcinoma. Immunohistochemical de-
termination of duct cells next to the basal membrane 
was conducted on the materials obtained by the tissue 
array method; tissue samples are obtained from paraf-
fin blocks of the tumor from three different locations 
using a biopsy needle. Considering the heterogeneity 
of the tumor tissue, this allows for testing different 
proteins on the same tumor cells. The basal cells were 
demonstrated through the application of the mouse 
monoclonal antibodies to CK 5/6 (DAKO, Clone: 
D5/16 B4; ready to use), CK 14 (Novocastra, Prod-
uct Code: NCL-LL002; Clone: LL002, 1:20) and P-
cadherin (Novocastra, Product Code: NCL-P-Cad, 
Clone 56C1; 1:50).
The method was performed through the machine 
use of immunohistochemical staining test tubes 
(DAKO autostainer, universal staining system) ac-
cording to the manufacturer’s recommendations, 
through the use of the Microwave Streptavidin Im-
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muno Peroxidase (MSIP) method and the diamin-
obenzidine (DAB) visualization system, found in the 
kit along with the secondary antibody and necessary 
reagents (Envision/HRP, K 5007; DAKO). The re-
sults of the immunohistochemical analysis of CK 5/6, 
CK 14 and P-cadherin were expressed using the fol-
lowing semi-quantitative method:
0  negative reaction no positivity in cell
  cytoplasm
+ weakly positive reaction <10% positive cells
++ moderately strong  10%-50% positive
 positive reaction cells
+++ strong positive reaction >50% positive cells
A positive reaction for one, two or three men-
tioned proteins implies a subtype of TNT invasive 
ductal breast carcinoma known as the basal-like tu-
mor. The tumor samples that did not have any of the 
three stated markers (proteins) were defined as triple 
negative non basal-like tumors. 
All analyses were performed with the use of IBM 
SPSS Statistics software, version 21 and OriginPro 
version 8.5. The receiver operating characteristic 
(ROC) curve was used to calculate specificity (true 
positive rate) and sensitivity (false positive rate). The 
area under the ROC curve (AUC) is a measure of how 
well a parameter can distinguish between two groups. 
The χ2-test was used to calculate the distribution of 
negative and positive values of CK 5/6, CK 14 and 
P-cadherin.
Results
The triple negative tumors collected from 150 pa-
tients were distributed into two groups based on im-
Table 1. Expression of each marker in basal like tumor 
cells
Marker Negative Positive Total
Cytokeratin 5/6 73 62.93% 43 37.07% 116 100%
Cytokeratin 14 57 46.14% 59 50.86% 116 100%
P-cadherin 36 31.03% 80 68.97% 116 100%
Cytokeratin 5/6 
and/or 14 46 39.66% 70 60.34% 116 100%
Fig. 1. Sensitivity of basal like tumor cells for each marker.
P-cadherin showed highest sensitivity for basal like tumors 
(69%), followed by cytokeratin 14 (50.9%) and cytokeratin 5/6 
(37.1%). The area under the curve (AUC) for P-cadherin was 
84.5%, for cytokeratin 75.4% and for cytokeratin 5/6 68.5%, 
yielding a statistically significant difference at the level of 
P=0.01.
Fig. 2. Response of basal like tumors to cytokeratin 5/6 
marker. 
Distribution of negative and positive values of cytokeratin 5/6 
showed a statistically significant difference (P=0.005).
munohistochemical analysis: 1) basal-like (BL), 116 
(77.33%) samples positive for one or all three markers 
(CK 5/6, CK 14 and P-cadherin); and 2) non basal- 
-like (NBL), 34 (22.67%) samples negative for all 
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The expression of each marker in basal-like tumor 
cells is illustrated in Table 1 and Figures 1-4. Cytok-
eratin 5/6 was found in the cells of 43 (37.07%), CK 14 
in 59 (50.86%), and P-cadherin in 80 (68.97%) tumor 
samples (Table 1).
Discussion
During a single year, 1.35 million women in the 
world are diagnosed with invasive breast cancer and 
450,000 women die. Despite significant advances in 
diagnosis and treatment methods for women with 
breast cancer, results are still far from being satisfac-
tory. Every new piece of information that could con-
tribute to understanding of cancer cell biology, which 
directly leads to better diagnosis and treatment, is 
very significant4.
Based on the expression of certain genes, 5 sub-
classes of breast tumors have been identified. The 
biggest difference in gene expression has been noted 
between HR positive and HR negative tumors.
Hormone receptor (HR) positive tumors are sub-
divided into two subgroups: luminal A (ER+, PR +, 
HER2-) and luminal B (ER+, PR+, HER2+). Both 
types express estrogen and progesterone genes but 
differ in their HER2 protein expression. They account 
for 60% of malignant breast tumors and have good 
prognosis. HR negative tumors are divided into three 
distinct subgroups: HER2 (ER-, PR-, HER2+), nor-
mal-like (ER±, PR±, HER2-), and basal-like (ER-, 
PR-, HER2-; triple negative tumors). They account 
for 40% of all cases of breast cancer12. They have vari-
ous prognoses and treatment options. In this sense, 
the worst prognosis and treatment options come with 
TNT, which do not express estrogen, progesterone 
and HER2 receptors. Furthermore, based on the 
analysis of gene activity, it has been confirmed that 
TNT are not homogeneous. The basal-like tumors 
make up the biggest part of the group of TNT (70%-
90%), while the rest are non basal-like. The basal-like 
subtype represents a homogeneous group of tumors 
sharing a common genetic profile, treatment response 
and prediction of the course of illness5,11,13,14.
So far, there has not been enough information 
about difference in the malignant potential of TNT 
considering the origin of cancer cells, and the ques-
tion being posed is whether differences in the progno-
sis and treatment among a small share of patients with 
triple negative cancer are a result of the malignant po-
tential within the TNT considering their basal-like 
and non basal-like origin.
This paper analyzes TNT collected from 150 pa-
tients distributed into two groups according to the 
results of immunohistochemical analysis, i.e. basal- 
-like (77.3%) and non basal-like (22.67%). However, 
Fig. 3. Response of basal like tumors to cytokeratin 14 
marker.
There was no statistically significant difference in the dis-
tribution of negative and positive values of cytokeratin 14 
(P=0.853).
Fig. 4. Response of basal like tumors to P-cadherin marker.
Distribution of negative and positive values of P-cadherin 
showed a statistically significant difference (P<0.001).
P - cadherin
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the immunohistochemical distribution of tumors using 
basal markers can be fairly unreliable. So, data from 
other research show a significant variation in the pres-
ence of basal-like tumors among the analyzed triple 
negative breast cancers, ranging from 42% to 88%9,15-17. 
However, our data on the distribution of each tumor 
subtype are in accordance with the data available, 
even those in which the classification was based on 
the expression of 500 different genes and where the 
presence of basal-like tumor was 71%9.
In order to increase the accuracy of the immuno-
histochemical distribution of tumors into basal-like 
and non basal-like, it is necessary to use as many dif-
ferent markers as possible, such as CK 5/6, CK 14, CK 
17, EGFR, P-cadherin, vimentin, fascin, nestin and 
moesin; they can be used individually or combined. 
Using each of the 9 markers for TNT would increase 
the share of basal-like tumors to up to 94% and this 
would include those that are not in correlation with 
the results obtained by the only valid gene expression 
analysis. Generally speaking, increasing the number 
of markers increases the test specificity and sensitiv-
ity10. However, as there is no general consensus on 
the criteria for identifying basal-like tumors through 
immunohistochemical analysis, it is recommendable 
to use a limited number of markers, such as CK 5/6, 
CK 14, CK 17, P-cadherin and EGFR5,11. The im-
munohistochemical reaction was positive for CK 5/6 
in 37%, for CK14 in 50.86% and for P-cadherin in 
68.34% of cases. The literature data available on the 
same markers show the following results: positive re-
action for CK 5/6 and CK 14 in 42%-88% and for 
P-cadherin in 93% of cases15.
Using the aforementioned combination (CK 5/6, 
CK 14 and P-cadherin) for identifying basal-like tu-
mors, we managed to identify the percentage of these 
tumors, which is closest to the results of the immuno-
histochemical analysis (65%-90%) and gene expres-
sion analysis (71%)5,14,17. The achieved result of 77.7% 
basal-like tumors indicates a good combination of 
basal markers used. 
The subclassification of triple negative breast can-
cers using the basal markers CK 5/6, CK 14 and P-
cadherin enabled identification of basal-like and non 
basal-like breast cancers in a proportion that is in line 
with the only accurate analysis of TNT gene expres-
sion. Using the mentioned combination of markers in 
everyday practice is easy to perform and economically 
affordable.
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Sažetak
IMUNOHISTOKEMIJSKA DIFERENCIJACIJA TROSTRUKO NEGATIVNOG RAKA DOJKE
M. Lesar, M. Stanec, N. Lesar, D. V. Vrdoljak, Z. Zore, M. Banović i G. Brozović
Na osnovi imunohistokemijske analize bazalnih biljega citokeratin 5/6 (CK 5/6), citokeratin 14 (CK 14) i P-kadherin 
trostruko negativni tumori (TNT) su podijeljeni u dvije skupine: 1. basal-like (BL) (pozitivni na jedan ili sva tri biljega) i 
2. non basal-like (NBL) (negativni na sva tri biljega). Iako različito podrijetlo stanica ovih dvaju tipova tumora upućuje i na 
njihova različita biološka svojstva, sve donedavno tretirani su kao jedan entitet. U našem su radu za identifikaciju basal-like 
tumora korišteni biljezi CK 5/6, CK 14 i P-kadherin. Imunohistokemijska reakacija na CK 5/6 bila je pozitivna u 37%, na 
CK 14 u 50,86% i na P-kadherin u 68,34% uzoraka. U ovom su radu TNT prikupljeni od ukupno 150 bolesnica razvrstani 
temeljem imunohistokemijske analize u dvije skupine: basal-like 116 (77,33%) i non basal-like 34 (22,67%). Subklasifikacija 
TNT dojke uz pomoć bazalnih biljega CK 5/6, CK 14 i P-kadherina omogućila je identifikaciju basal-like i non basal-like 
tumora dojke u omjeru koji je u skladu s jedino točnom analizom genske ekspresije TNT. Primjena navedene kombinacije 
biljega u svakodnevnoj je praksi lako izvediva i ekonomski nezahtjevna.
Ključne riječi: Karcinom dojke, duktalni; Trostruko negativni tumori dojke; Biomarkeri, tumorski; Bazalni tumori; Nebazal-
ni tumori; Odrasla osoba
